Introduction to SNORD126 (G100113391)

Target Name: SNORD126

NCBI ID: G100113391

SNORD126

Other Name(s): MIRN1201 | MIR1201 | small nucleolar RNA, C/D box 126 | Small nucleolar RNA, C/D box 126

Introduction to SNORD126
SNORD126, also known as small nucleolar RNA, C/D box 126, is an important molecule in the field of medical research. It has recently gained attention as a potential drug target or biomarker due to its crucial role in various biological processes. In this article, we will delve into the significance of SNORD126 and explore its potential applications in the diagnosis and treatment of various diseases.

What is SNORD126?
SNORD126 is a small nucleolar RNA (snoRNA) molecule that belongs to the C/D box class of snoRNAs. These molecules play a critical role in the post-transcriptional modification of ribosomal RNA (rRNA) and other non-coding RNAs. SNORD126, in particular, is responsible for the 2'-O-methylation of the ribose sugar at position 1832 of the 28S rRNA, an essential modification for efficient ribosome function.

Role as a Drug Target:
Due to its involvement in ribosome function, SNORD126 has emerged as a potential drug target for various diseases, particularly cancers. The dysregulation of snoRNAs, including SNORD126, has been observed in multiple cancer types, suggesting their crucial role in tumorigenesis and disease progression. Targeting SNORD126 with specific inhibitors or modulators could potentially disrupt ribosome function in cancer cells, leading to their selective growth inhibition or cell death.

Several studies have demonstrated the effectiveness of snoRNA-based therapies in preclinical cancer models. For instance, the knockdown of certain snoRNAs, including SNORD126, using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs), has shown promising results in suppressing tumor growth and metastasis. The specific targeting of SNORD126 in cancer cells could potentially provide a viable and specific therapeutic strategy with minimal off-target effects.

Potential Biomarker:
In addition to its potential as a drug target, SNORD126 has also shown promise as a biomarker for various diseases. Several studies have shown altered expression levels of SNORD126 in different cancers, such as lung cancer, breast cancer, and colorectal cancer. These alterations in expression levels could potentially serve as diagnostic or prognostic indicators for specific cancers.

For example, a study published in the journal Oncotarget examined the expression levels of snoRNAs, including SNORD126, in non-small cell lung cancer (NSCLC) patients. The researchers observed lower expression levels of SNORD126 in NSCLC tumors compared to adjacent healthy tissues. Furthermore, low expression levels of SNORD126 were associated with worse overall survival rates in NSCLC patients. This significant correlation suggests the potential of SNORD126 as a prognostic biomarker for NSCLC.

Moreover, SNORD126 expression levels have also been implicated in the development of drug resistance in certain cancers. A study published in Nature Communications demonstrated that SNORD126-mediated 2'-O-methylation of rRNA was necessary for the response to specific chemotherapeutic drugs. Disrupting SNORD126 expression or its functional activity led to increased resistance to these drugs. Therefore, monitoring SNORD126 levels could potentially aid in predicting drug responsiveness and optimizing treatment strategies for patients.

Conclusion:
SNORD126, a vital snoRNA molecule, has shown immense potential as both a drug target and a biomarker in various diseases, particularly cancers. Its involvement in ribosome function and dysregulation in cancer suggest its potential as a therapeutic target. Additionally, altered expression levels of SNORD126 in cancers and its impact on drug responsiveness make it a potential biomarker for diagnosis, prognosis, and treatment selection. Further research and clinical validation are necessary to fully realize the therapeutic and diagnostic potential of SNORD126. Nonetheless, SNORD126 holds exciting prospects for improving patient outcomes and advancing precision medicine.

Protein Name: Small Nucleolar RNA, C/D Box 126

The "SNORD126 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD126 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets